HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Structural heart disease

TAVR in Pure Native Aortic Regurgitation: Are Dedicated Devices Truly Superior?

This systematic meta-analysis assessed the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

Transradial Aortic Valvuloplasty: Is Minimalism Worth It?

Balloon aortic valvuloplasty (BAV) has historically been used either as a bridge strategy, an assessment tool, or...
Dr. Omar Tupayachi -
Learn More
Structural heart disease

TCT 2025 | SUMMIT-MAC: Transcatheter Mitral Valve Replacement with the Tendyne System in Patients with Severe Annular Calcification

The prospective, multicenter SUMMIT-MAC study evaluated the safety and efficacy of transcatheter mitral valve replacement (TMVR) using...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

TCT 2025 | PREVUE-VALVE: Prevalence of Valvular Heart Disease in Elderly US Patients

The PREVUE-VALVE study was designed to determine the true prevalence and demographic determinants of valvular heart disease...
Dr. Juan Manuel Pérez -
Learn More
Mitral valve

TCT 2025 | Transcatheter Mitral Valve Replacement with SAPIEN M3: ENCIRCLE 1-Year Outcomes

Transcatheter mitral valve replacement (TMVR) is an emerging option for patients with symptomatic mitral regurgitation (MR) who...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

TCT 2025 | PARTNER 3 Trial 7-Year Outcomes: TAVR vs SAVR in Low-Risk Patients

The randomized PARTNER 3, which initially showed TAVR superiority when using the SAPIEN 3 valve over SAVR...
Dr. Juan Manuel Pérez -
Learn More